+

BR0314195A - Derivados de piridina substituìda como agentes antitumorais - Google Patents

Derivados de piridina substituìda como agentes antitumorais

Info

Publication number
BR0314195A
BR0314195A BR0314195-0A BR0314195A BR0314195A BR 0314195 A BR0314195 A BR 0314195A BR 0314195 A BR0314195 A BR 0314195A BR 0314195 A BR0314195 A BR 0314195A
Authority
BR
Brazil
Prior art keywords
pyridine derivatives
substituted pyridine
antitumor agents
agents
antitumor
Prior art date
Application number
BR0314195-0A
Other languages
English (en)
Inventor
Mauro Angiolini
Maria Menichincheri
Domenico Fusar Bassini
Markus Gude
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0314195A publication Critical patent/BR0314195A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE PIRIDINA SUBSTITUìDA COMO AGENTES ANTITUMORAIS". A presente invenção refere-se a novos derivados de piridina substituída, ativos como inibidores de telomerase, seu uso como agentes terapêuticos, particularmente como agentes antitumorais, um processo para a sua preparação, e composições farmacêuticas que os compreendem.
BR0314195-0A 2002-09-10 2003-08-26 Derivados de piridina substituìda como agentes antitumorais BR0314195A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40947102P 2002-09-10 2002-09-10
PCT/EP2003/009572 WO2004024711A1 (en) 2002-09-10 2003-08-26 Substituted pyridine derivatives as antitumor agent

Publications (1)

Publication Number Publication Date
BR0314195A true BR0314195A (pt) 2005-07-26

Family

ID=31993972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314195-0A BR0314195A (pt) 2002-09-10 2003-08-26 Derivados de piridina substituìda como agentes antitumorais

Country Status (7)

Country Link
EP (1) EP1546129A1 (pt)
JP (1) JP2006503028A (pt)
AU (1) AU2003260472A1 (pt)
BR (1) BR0314195A (pt)
CA (1) CA2498281A1 (pt)
MX (1) MXPA05001883A (pt)
WO (1) WO2004024711A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013308A (es) 2006-04-19 2008-10-27 Serono Lab Nuevos derivados de arilaminopiridina heteroaril-sustituidos como inhibidores de mek.
EP2144877A1 (en) * 2007-04-04 2010-01-20 UCB Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN107935992A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一类含金刚烷和卤代吡啶结构化合物及用途
CN108129457A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷ssao抑制剂、制备方法及其用途
CN108084154A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途
CN107935990A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途
CN108191825A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和硝基吡啶结构衍生物及其用途
CN107935991A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一种甲基金刚烷和胺基吡啶结构衍生物、其制备方法及其用途
CN108084155A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途
CN108191823A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途
CN107915719A (zh) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途
CN108191824A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途
CN108033946A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种含金刚烷结构的ssao抑制剂、制备方法及其用途
CN107935993A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途
CN108033945A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种金刚烷和硝基吡啶结构化合物及用途
CN107935989A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 金刚烷和腈基吡啶结构化合物、其制备方法及用途
CN108129458A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途
CN109988147A (zh) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 含金刚烷结构的ssao抑制剂、制备方法及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1363415A (en) * 1970-08-04 1974-08-14 Ici Ltd Bis-pyridyl amine compounds
PL355667A1 (en) * 1999-11-29 2004-05-04 Aventis Pharma S.A. Arylamine derivatives and their use as anti-telomerase agent

Also Published As

Publication number Publication date
MXPA05001883A (es) 2005-06-03
JP2006503028A (ja) 2006-01-26
WO2004024711A1 (en) 2004-03-25
CA2498281A1 (en) 2004-03-25
EP1546129A1 (en) 2005-06-29
AU2003260472A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
PA8551001A1 (es) Nuevos compuestos
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BR0108678A (pt) Novos compostos
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
BR0316680A (pt) Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
BR0208338A (pt) Derivados de piridina
SE9904505D0 (sv) Novel compounds
BRPI0113146B8 (pt) "derivados de prolina e composição farmacêutica que os compreende".
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载